GenVec President & CEO Cynthia Collins Joins BioHealth Innovation, Inc. Board of Directors

GenVec President & CEO Cynthia Collins Joins BioHealth Innovation, Inc. Board
                                 of Directors

PR Newswire

ROCKVILLE, Md., Feb. 11, 2013

ROCKVILLE, Md., Feb. 11, 2013 /PRNewswire/ --BioHealth Innovation, Inc.
(BHI), a regional private-public partnership focusing on commercializing
market-relevant biohealth innovations and increasing access to early-stage
funding in Central Maryland, announced today the appointment of GenVec, Inc.
President and Chief Executive Officer Cynthia L. Collins to its Board of
Directors. BHI also announced that BHI Founding Board Member Jerry Parrott,
formerly with Human Genome Sciences, has stepped down from his board seat but
will continue to remain active on BHI's Commercial Relevance Advisory Board.

"Cindy's addition to the BHI Board of Directors provides us with access to and
perspective from another talented biopharma leader from this region," said
Scott Carmer, BioHealth Innovation, Inc. Chairman of the Board and Executive
Vice President of Commercial Operations at MedImmune. "Her tremendous depth
and breadth of experience across the industry, particularly with regard to
diagnostics as well as therapeutic areas ranging from antivirals to oncology,
will be an asset to the companies we work with who are seeking to
commercialize biohealth innovations.

"On behalf of the entire BHI Board, I would also like to thank Jerry Parrott
for his contributions to BHI as a founding board member," added Mr. Carmer.
"Fortunately, Jerry will continue to work with BHI via its Commercial
Relevance Advisory Board."

Ms. Collins has served as President and Chief Executive Officer and as a
director of GenVec, Inc. since May 2012. Ms. Collins previously served as
Group Vice President, Cellular Analysis Business, Beckman Coulter from 2007
until its sale in 2011. Prior to joining Beckman Coulter, Ms. Collins served
as Chief Executive Officer of Sequoia Pharmaceuticals, Inc., a private
biotechnology company developing antiviral drugs. Prior to joining Sequoia,
Ms. Collins was President of Clinical Micro Sensors, Inc., a wholly owned
subsidiary of Motorola where she directed the development and
commercialization of molecular diagnostic microarray products and led the
eventual strategic divestiture of the division. Before Motorola, she spent
over 17 years at Baxter Healthcare in a variety of executive roles, including
President of Global Oncology and Vice President of Strategy and Portfolio
Management of BioScience. Previously, she spent six years with Abbott
Laboratories in a series of operational assignments. Ms. Collins received her
undergraduate degree in Microbiology from the University of Illinois and her
Masters in Business Administration from the University of Chicago Graduate
School of Business.

"I am deeply honored to join an already talented and robust Board of Directors
at BHI," said Ms. Collins. "BHI's focus on early-stage funding and
collaborations within this industry and Maryland line-up with one of my goal's
as the leader of a growing biotechnology company in this region."

About BioHealth Innovation, Inc.
BioHealth Innovation, Inc., is a regional innovation intermediary focused on
commercializing market-relevant bio-health innovations and increasing access
to early-stage funding in Maryland. Learn more at

SOURCE BioHealth Innovation, Inc.

Contact: Rich Bendis, President & CEO, +1-301-637-6439,
Press spacebar to pause and continue. Press esc to stop.